TherapeuticsMD, Inc. announced the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 USD | -3.23% | -3.67% | -6.67% |
05-10 | TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-10 | TherapeuticsMD, Inc. Continues Evaluation of Strategic Alternatives | CI |
1st Jan change | Capi. | |
---|---|---|
-6.67% | 25.03M | |
+18.49% | 78.7B | |
+14.09% | 9.26B | |
-15.14% | 4.92B | |
+45.17% | 4.66B | |
+15.70% | 4.27B | |
+16.71% | 2.44B | |
-26.13% | 2.22B | |
+15.73% | 2.15B | |
-40.52% | 1.89B |
- Stock Market
- Equities
- TXMD Stock
- News TherapeuticsMD, Inc.
- Therapeuticsmd, Inc. Announces Chief Executive Officer Changes